openPR Logo
Press release

Generic Musculoskeletal Disorders Drugs Market Poised for 7 % Growth, Set to Hit $0.08 Billion by 2029

02-27-2025 11:36 AM CET | Health & Medicine

Press release from: The Business Research Company

Generic Musculoskeletal Disorders Drugs Market

Generic Musculoskeletal Disorders Drugs Market

What industry-specific factors are fueling the growth of the generic musculoskeletal disorders drugs market?
The considerable incidence of arthritis is anticipated to fuel the expansion of the generic musculoskeletal disorders drugs market. Arthritis, characterized by joint tenderness, swelling, pain, and stiffness, benefits greatly from generic musculoskeletal disorders drugs which alleviate discomfort and stiffness in the muscles and address muscle spasms in patients with arthritis. For example, in March 2022, Versus Arthritis, a charity based in the UK, published data that revealed approximately 10 million people in the UK were diagnosed with osteoarthritis, which included 5.4 million with knee OA, 3.2 million with hip OA, and about 450,000 with rheumatoid arthritis coupled with 190,000 having psoriatic arthritis. This signifies over 20 million individuals coping with musculoskeletal conditions, leading to more than 30 million prescriptions that were dispensed for these conditions costing roughly £139 million in the year 2022-2023. Therefore, the significant incidence of arthritis is acting as a catalyst for the growth of the generic musculoskeletal disorders drugs market.

Get Your Generic Musculoskeletal Disorders Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/generic-musculoskeletal-disorders-drugs-global-market-report

What Is the projected market size and growth rate for the generic musculoskeletal disorders drugs market?
The market size for generic drugs for musculoskeletal disorders has been witnessing steady growth over the recent years. The market, proliferating from $0.06 billion in 2024, is predicted to reach $0.06 billion in 2025, registering a compound annual growth rate (CAGR) of 6.7%. The growth during the historical period can be credited to the prevalence of musculoskeletal disorders, regulatory framework, development in healthcare infrastructure, patient awareness and education, and economic factors.

The market size for generic drugs pertaining to musculoskeletal disorders is projected to experience robust expansion in the upcoming years, reaching $0.08 billion by 2029, with a compound annual growth rate (CAGR) of 7.2%. The growth anticipated during the forecast period is influenced by an increase in population and aging, the emergence of new markets, precision medicine, personalized therapies, healthcare reforms, and global health trends. Key trends expected to be seen throughout this period consist of the incorporation of technology in treatments, initiatives and healthcare policies by the government, a shift towards alternatives for pain management, a surge in the acceptance of biosimilars, and progress in the development of generic drugs.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9433&type=smp

What new trends are reshaping the generic musculoskeletal disorders drugs market and its opportunities?
The increasing trend of strategic collaborations is becoming quite significant in the generic musculoskeletal disorders drugs market. Several firms in this market are entering into partnerships to boost their market standing. For example, in July 2022, Mitsubishi Tanabe Pharma Corporation, originated from Japan, entered into a business tie-up with Eli Lilly and Company, a pharma company based in the US. This collaboration allows the two companies to expand their product offerings and provide patients with effective treatment solutions for conditions like diabetes among other diseases. Furthermore, in February 2022, Pfizer Inc, a US-led pharmaceutical and biotech giant, established a partnership with Alex Therapeutics, a digital therapeutics firm based in Sweden. This innovative strategic partnership provides patients with evidence-supported, clinically validated, and personalized digital therapeutics.

What major market segments define the scope and growth of the generic musculoskeletal disorders drugs market?
The generic musculoskeletal disorders drugs market covered in this report is segmented -

1) By Treatment Type: Medication, Therapy, Surgery, Other Treatment Types
2) By Disorder Type: Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types
3) By Route Of Administration: Oral, Parenteral, Other Routes
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy

Subsegments:
1) By Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics, Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologics
2) By Therapy: Physical Therapy, Occupational Therapy, Chiropractic Treatment, Massage Therapy
3) By Surgery: Joint Replacement Surgery, Arthroscopy, Spinal Surgery, Fusion Surgery
4) By Other Treatment Types: Lifestyle Modifications, Alternative Therapies, Assistive Devices

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9433

Which region dominates the generic musculoskeletal disorders drugs market?
Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2024. The regions covered in the generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the generic musculoskeletal disorders drugs industry growth?
Major companies operating in the generic musculoskeletal disorders drugs market include Pfizer Inc., Sanofi S.A., Eli Lilly and Company, Ampio Pharmaceuticals Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca plc, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Eisai Co. Ltd., Biogen Inc., Sino Biopharmaceutical Limited, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Mylan Pharmaceuticals Inc., Taisho Pharmaceutical Holdings Co. Ltd., Flexion Therapeutics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9433&type=smp

What Is Covered In The Generic Musculoskeletal Disorders Drugs Global Market Report?

• Market Size Forecast: Examine the generic musculoskeletal disorders drugs market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the generic musculoskeletal disorders drugs market for a structured understanding.
• Key Players Overview: Analyze major players in the generic musculoskeletal disorders drugs market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the generic musculoskeletal disorders drugs market.
• Segment Contributions: Evaluate how different segments drive overall growth in the generic musculoskeletal disorders drugs market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the generic musculoskeletal disorders drugs market.
• Industry Challenges: Identify potential risks and obstacles affecting the generic musculoskeletal disorders drugs market.
• Competitive Landscape: Review strategic developments in the generic musculoskeletal disorders drugs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic Musculoskeletal Disorders Drugs Market Poised for 7 % Growth, Set to Hit $0.08 Billion by 2029 here

News-ID: 3890257 • Views:

More Releases from The Business Research Company

Percutaneous Puncture Surgery Robot Market Analysis Highlights Growth To $3.54 Billion By 2030 At 12.2% CAGR
Percutaneous Puncture Surgery Robot Market Analysis Highlights Growth To $3.54 B …
The market for percutaneous puncture surgery robots is on the verge of significant expansion, driven by rapid technological advances and increasing adoption in healthcare settings. As robotic systems become more sophisticated and integrated with cutting-edge technologies, this sector is set to transform minimally invasive surgical procedures. Below is a detailed exploration of the market's size, key players, trends, and segmentation that shape its future trajectory. Projected Growth and Market Size of
Pedicle Screw Systems Market Study Highlights How Industry Demand Is Evolving
Pedicle Screw Systems Market Study Highlights How Industry Demand Is Evolving
The pedicle screw systems market is set to experience significant expansion in the coming years, driven by advancements in spinal surgery techniques and increasing patient demand. This market's evolution reflects growing medical needs and ongoing innovation, positioning it for substantial growth by 2030. Forecasted Market Size and Growth Trajectory for Pedicle Screw Systems The value of the pedicle screw systems market is projected to reach $7.65 billion by 2030, growing
Pediatric Orthopedic Implants Market Research Reveals Strong 10.8% CAGR Outlook Through 2030
Pediatric Orthopedic Implants Market Research Reveals Strong 10.8% CAGR Outlook …
The pediatric orthopedic implants market is on track for significant expansion as advancements in technology and growing healthcare needs drive demand. Innovations in implant design and personalized treatment options are setting the stage for transformative growth in this specialized segment of medical devices. Below is a detailed overview of the current market size, key industry players, emerging trends, and segmentation that define this market's future. Pediatric Orthopedic Implants Market Size and
Pediatric Interventional Cardiology Market Intelligence Report Covers Trends, Segments And Regional Growth
Pediatric Interventional Cardiology Market Intelligence Report Covers Trends, Se …
The pediatric interventional cardiology field is on track for significant expansion, driven by advances in medical technology and growing demand for specialized cardiac care for children. This sector is expected to see dynamic growth as innovative devices and techniques become more widely adopted to improve patient outcomes. Projected Market Size and Growth Trajectory of the Pediatric Interventional Cardiology Market The market for pediatric interventional cardiology is forecasted to grow steadily,

All 5 Releases


More Releases for Pharma

Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others. DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others. DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring